Leading Oncology Education With the FLASCO Rapid Integrations Program
The Rapid Integration Program, a training initiative for new physician’s assistants and nurse practitioners working in the field of oncology, is a Florida Society of Community Oncology (FLASCO) initiative that came from an ASCO meeting. Winston Tan, MD, of the Head and Neck Cancer Center at the Mayo Clinic in Jacksonville, Florida, speaking during the 2019 ASCO Annual Meeting, was in attendance at the 2016 ASCO Annual Meeting when the idea for a training program was first introduced.<br />
The Rapid Integration Program, a training initiative for new physician’s assistants and nurse practitioners working in the field of oncology, is a Florida Society of Community Oncology (FLASCO) initiative that came from an ASCO meeting. Winston Tan, MD, of the Head and Neck Cancer Center at the Mayo Clinic in Jacksonville, Florida, speaking during the 2019 ASCO Annual Meeting, was in attendance at the 2016 ASCO Annual Meeting when the idea for a training program was first introduced.
Prior to the formation of the Rapid Integrations Program, Tans explains, there was a knowledge gap, and advanced practice providers (APPs) needed to have a better understanding of hematology/oncology basics, how to integrate into private or academic practices, communicating with patients, clinical trials, the business of oncology, and more. The need for more education led to a one-day course held twice per year (the Rapid Integrations Course) in the state of Florida during which experienced APPs speak before those that are new to the field. Eventually, FLASCO also formed the Making Strides Program, a similar initiative to the Rapid Integrations Program, which educates experienced clinicians on the same hematology/oncology topics to meet the need for seasoned APPs to learn the latest advances in the field.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
